Cargando…
A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
We explored in a phase I/II clinical trial the combination of valproic acid (VPA), a clinically available histone deacetylase inhibitor, with standard chemoimmunotherapy in patients with advanced melanoma, to evaluate its clinical activity, to correlate the clinical response with the biological acti...
Autores principales: | Rocca, A, Minucci, S, Tosti, G, Croci, D, Contegno, F, Ballarini, M, Nolè, F, Munzone, E, Salmaggi, A, Goldhirsch, A, Pelicci, P G, Testori, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634690/ https://www.ncbi.nlm.nih.gov/pubmed/19127265 http://dx.doi.org/10.1038/sj.bjc.6604817 |
Ejemplares similares
-
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006) -
Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006) -
Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples
por: Berendsen, Sharon, et al.
Publicado: (2019) -
Effects of the Histone Deacetylase Inhibitor Valproic Acid on Human Pericytes In Vitro
por: Karén, Jakob, et al.
Publicado: (2011) -
Effects of histone deacetylase inhibitor valproic acid on skeletal myocyte development
por: Li, Qiao, et al.
Publicado: (2014)